167 related articles for article (PubMed ID: 37770652)
1. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M; Forleo-Neto E; Pignolo RJ; Keen R; Orcel P; Funck-Brentano T; Roux C; Kolta S; Madeo A; Bubbear JS; Tabarkiewicz J; Szczepanek M; Bachiller-Corral J; Cheung AM; Dahir KM; Botman E; Raijmakers PG; Al Mukaddam M; Tile L; Portal-Celhay C; Sarkar N; Hou P; Musser BJ; Boyapati A; Mohammadi K; Mellis SJ; Rankin AJ; Economides AN; Trotter DG; Herman GA; O'Meara SJ; DelGizzi R; Weinreich DM; Yancopoulos GD; Eekhoff EMW; Kaplan FS
Nat Med; 2023 Oct; 29(10):2615-2624. PubMed ID: 37770652
[TBL] [Abstract][Full Text] [Related]
2. Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 Trial.
Wang Y; Nguyen JH; de Ruiter RD; Mendell J; Srinivasan D; Davis JD; Eekhoff EMW
J Clin Pharmacol; 2024 Feb; 64(2):264-274. PubMed ID: 37694449
[TBL] [Abstract][Full Text] [Related]
3. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
4. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract][Full Text] [Related]
5. Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: An [
Botman E; Raijmakers PGHM; Yaqub M; Teunissen B; Netelenbos C; Lubbers W; Schwarte LA; Micha D; Bravenboer N; Schoenmaker T; de Vries TJ; Pals G; Smit JM; Koolwijk P; Trotter DG; Lammertsma AA; Eekhoff EMW
Bone; 2019 Jul; 124():1-6. PubMed ID: 30858149
[TBL] [Abstract][Full Text] [Related]
6. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
7. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
8. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
9. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
Eekhoff EMW; Botman E; Coen Netelenbos J; de Graaf P; Bravenboer N; Micha D; Pals G; de Vries TJ; Schoenmaker T; Hoebink M; Lammertsma AA; Raijmakers PGHM
Bone; 2018 Apr; 109():143-146. PubMed ID: 28826841
[TBL] [Abstract][Full Text] [Related]
10. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.
Pignolo RJ; Baujat G; Brown MA; De Cunto C; Di Rocco M; Hsiao EC; Keen R; Al Mukaddam M; Sang KLQ; Wilson A; White B; Grogan DR; Kaplan FS
Orphanet J Rare Dis; 2019 May; 14(1):98. PubMed ID: 31053156
[TBL] [Abstract][Full Text] [Related]
11. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
12. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature.
Botman E; Netelenbos JC; Rustemeyer T; Schoonmade LJ; Nieuwenhuijzen JA; Teunissen BP; Visser M; Raijmakers P; Lammertsma AA; Dahele M; Eekhoff M
Front Endocrinol (Lausanne); 2020; 11():6. PubMed ID: 32117050
[TBL] [Abstract][Full Text] [Related]
14. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
15. Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Wang H; Zhang Q; Kaplan FS; Pignolo RJ
J Bone Miner Res; 2022 Jan; 37(1):95-107. PubMed ID: 34633114
[TBL] [Abstract][Full Text] [Related]
16. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study.
Vanhoutte F; Liang S; Ruddy M; Zhao A; Drewery T; Wang Y; DelGizzi R; Forleo-Neto E; Rajadhyaksha M; Herman G; Davis JD
J Clin Pharmacol; 2020 Nov; 60(11):1424-1431. PubMed ID: 32557665
[TBL] [Abstract][Full Text] [Related]
18. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K
Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?
Grgurević L; Novak R; Trkulja V; Hamzić LF; Hrkač S; Grazio S; Santini M
Med Hypotheses; 2019 Oct; 131():109313. PubMed ID: 31443758
[TBL] [Abstract][Full Text] [Related]
20. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
